Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Posted on

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Buttigliero C, Shepherd FA, Barlesi F, et al. Oncologist. 2018 Aug 23


VeriStrat testing was predictive of outcomes, independent of other clinical variables including ECOG performance status, treatment, and mutational status.

 

Study Objective

Investigate the value of VeriStrat in patients with NSCLC.
 

Study Endpoint

Overall survival (OS) and progression-free survival (PFS), with analysis of other clinical variables including ECOG performance score, patient EGFR mutation status and treatment received.
 

Methods

For both patient cohorts (N = 996), VeriStrat test results (VeriStrat Good or VeriStrat Poor) were acquired prior to treatment with either tivantinib plus erlotinib or placebo plus erlotinib.
 

Results

Independent of treatment arm, patients who were classified as VeriStrat Good had significantly longer PFS and OS than patients classified as VeriStrat Poor. The VeriStrat Good population had increased OS than the VeriStrat Poor population within ECOG performance score categories. Patients with a VeriStrat Poor result and a better ECOG performance score (PS 0) had a worse OS compared to VeriStrat Good patients with a worse performance score (PS 1). In the EGFR mutation-positive subgroup, patients with a VeriStrat Good result experienced improved OS as compared to patients with a VeriStrat Poor result when treated with a single-agent EGFR-TKI.
 

Study Conclusion

VeriStrat results were predictive of outcomes, independent of other clinical variables including ECOG performance status, mutation status and treatment received. VeriStrat showed a predictive role within ECOG performance score categories and independently of treatment arm and EGFR status, suggesting that VeriStrat could be used to identify EGFR mutation-positive patients who will have a poor response to EGFR TKIs.